NLS-1 Pharma AG
Records under this name other than patents NLS-1 Pharma AG holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 6 of 6 · Back to NLS-1 Pharma AG
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,293,779 | Mazindol Combination in the Treatment of Attention Deficit/Hyperactivity Formerly held In force · High confidence | In force | High confidence | |
| US 11,207,271 | Mazindol IR/SR multilayer tablet and its use for the treatment of attention deficit/hyperactivity disorder (ADHD) Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 11,596,622 | Mazindol Treatment for Heroin Dependence and Substance Use Disorder Formerly held In force · High confidence | In force | High confidence | |
| US 9,637,447 | Lauflumide and the Enantiomers Thereof, Method for Preparing Same and Therapeutic Uses Thereof Formerly held Lapsed on the fee record Ended May 2, 2025 · High confidence | Lapsed on the fee record | Ended May 2, 2025 | High confidence |
| US 10,532,100 | Use of iron for treating attention deficit hyperactivity disorder in children Formerly held Lapsed on the fee record Ended Jan 14, 2024 · High confidence | Lapsed on the fee record | Ended Jan 14, 2024 | High confidence |
| US 10,456,387 | Phacetoperane for treating of attention deficit hyperactivity disorder Formerly held Lapsed on the fee record Ended Oct 29, 2023 · From the USPTO record | Lapsed on the fee record | Ended Oct 29, 2023 | From the USPTO record |